			Total Estimated				
Contract Number	Amo	unt Obligated	Contract Value	Awardee Name	Awardee Address	Awardee Zip Code	Description of Requirement
	1	ant obligated	Communication and Communicatio	7.110.000.110.110	7.1.4.4.0.0.7.4.4.1.0.0.0	rtttalace z.p coac	Conduct a study entitled, " Development of
75F40120C00158	\$	11,106,465.00	\$ 11.106.465.00	CERUS CORP 1457308	1220 CONCORD DRIVE SUITE 600	CA 94520-4813	an optimized pathogen inactivation process
70. 10110000	+		Ψ ==)=σσ) :σσ:σσ	2.000		0.1010101010	study entitled, "Identification of Critical
					GEORGIA TECH RESEARCH		Quality Attributes of Cell Therapy Products
				GEORGIA TECH RESEARCH CORP	CORPORATION 926 DALNEY ST NW		by Multi-Omics Analyses and Predictive
75F40120C00207	\$	1,470,387.82	\$ 1,470,387.82	160612	ATLANTA	GA 30318	Modeling"
73140120000207	+	1,470,387.82	γ 1,470,367.62	UNIVERSITY OF GEORGIA	ATLANTA	UA 30318	study entitled, "Salmonella source
				RESEARCH FOUNDATION INC	621-630 GRADUATE STUDIES		attribution by machine learning and whole
75540420000407	Ś	200 014 00	ć 200.014.00			CA 20C02 7411	
75F40120C00187	+	298,914.00	\$ 298,914.00	104442	ATHENS	GA 30602-7411	genome sequencing"
75F40120C00161	١	1,299,875.92	\$ 3,153,835.91	CONCEPTANT INC 1497637	7323 ELMWOOD DR FALLS CHURCH	VA 22042-1409	Optimizing Regulatory Affairs Operations
73140120000101	+	1,233,073.32	3,133,633.31	CONCENTANT INC 1437037	7323 ELIVIWOOD DICTALES CHOREIT	VA 22042-1403	study entitled, "A Quantitative Approach to
				NORTH CAROLINA STATE	2700 SULLIVAN DR STE 7514		Assessing Drug Supply Chain Disruptions
75F40120C00124	Ś	100,000.00	¢ 100,000,00	UNIVERSITY 180521	RALEIGH	NC 27695-7514	Leading to Shortages."
73F40120C00124	+	100,000.00	\$ 100,000.00	UNIVERSITY 180321	KALEIGH	NC 27095-7514	-
							study entitled "Incidence and Outcomes of
					CHU PRENIC HOCRITAL OF		Human Adenovirus Infection
					CHILDREN'S HOSPITAL OF		and Disease among a Multicenter
					PHILADELPHIA		Observational Cohort of Pediatric Allogeneic
				THE CHILDREN'S HOSPITAL OF	3401 CIVIC CENTER BLVD		Hematopoietic
75F40120C00135	\$	347,335.00	\$ 347,335.00	PHILADELPHIA 356961	PHILADELPHIA	PA 19104-4319	Cell Transplant Recipients"
							conduct a study entitled, "Master Data
							Management Informatics Analysis for the
					5201 GREAT AMERICA PKWY STE		Center for Drug
75F40120C00154	\$	1,062,995.00	\$ 4,551,098.00	LUMENDATA INC. 1468150	320 SANTA CLARA	CA 95054-1140	Evaluation and Research (CDER)."
							study entitled, "Benefit-Risk Preferences for
					RESEARCH TRIANGLE INSTITUTE 30		the use of artificial
				RESEARCH TRIANGLE INSTITUTE	3040 E CORNWALLIS RD		intelligence and machine learning in imaging
75F40120C00194	\$	436,800.00	\$ 436,800.00	105107	RESEARCH TRIANGLE PARK	NC 27709-0155	diagnostics".
							study entitled, "Evaluating physical
							functioning using patient-reported outcome
75F40120C00069	\$	696,359.00	\$ 696,359.00	DUKE UNIVERSITY 132317	2200 W MAIN ST STE 710 DURHAM	NC 27708-4677	measures: How does the question form and
							study entitled, "Quantifying Patients' Benefit-
							Risk Tradeoffs Associated
							with Percutaneous Revascularization Options
							for Peripheral Arterial Disease: A
							Collaborative
							Effort with the RAPID PATHWAYS Patient
75F40120C00179	\$	1,092,665.00	\$ 1,664,528.00	DUKE UNIVERSITY 132317	2200 W MAIN ST STE 710 DURHAM	NC 27708-4677	Science Working Group."
	1	· · ·					study entitled, "Characterization of severe
					THE		coronavirus infection in
					FOUNDATION BUILDING, 765		humans and model systems for medical
					BROWNLOW	MERSEYSIDE L69 77X	countermeasure development and
75F40120C00085	\$	5,402,198.00	\$ 6.634.520.00	THE UNIVERSITY OF LIVERPOOL	HILL, LIVERPOOL,	•	evaluation
. 5. 1012000005	+-	5, .02,130.00	7 0,007,020.00	State S	LELAND STANFORD JUNIOR	5 25 KII (a study entitled, "Pathology and
					UNIVERSITY, 450 JANE STANFORD		Pathogenesis of Coronavirus Infections in
75F40120C00176	رخ	1,550,500.00	\$ 3 448 008 00	STANEORD LINIVERSITY 217601	WAY STANFORD	CA 94305-2004	Animal Models
/364012000176	<u> </u>	1,550,500.00	3,448,008.00	STANFORD UNIVERSITY 217691	WAT STAINFURD	CA 34303-2004	Animal Models

			Total Estimated				
Contract Number	Amo	unt Obligated	Contract Value	Awardee Name	Awardee Address	Awardee Zip Code	Description of Requirement
75F40120C00021	\$	973,184.00	\$ 973,184.00	UNIVERSITY OF CONNECTICUT 297690	438 WHITNEY RD EXTENSION UNIT 1133 STORRS	CT 06269-1133	Study entitled, "Impact of Polymer Attributes on the Performance of in Situ Forming Implants, Improved Scientific Approaches to Evaluate Generic Drugs"
75F40120C00036	\$	129,469.00	\$ 129,469.00	NANOPHARM LTD 1558826	5 LEEDS TWEN 5 LEEDS TWENTY- SEVEN INDUSTRIAL EST LEEDS WEST	YORKSHIRE LS27	study entitled, "INVESTIGATING ORTHOGONAL ANALYTICAL APPROACHES TO DEMONSTRATE BIOEQUIVALENCE OF NASAL SUSPENSION FORMULATIONS."
75F40120C00055	\$	567,980.00	\$ 567,980.00	LANDRAU SCIENTIFIC INNOVATIONS LLC 1560241	LANDRAU SCIENTIFIC INNOVATIONS, LLC , 17 DEVENS ST MARLBOROUGH	MA 01752-2207	study entitled, "Evaluation of Critical Process Parameters for the Preparation of Amphotericin B That Influence Toxicity".
75F40120C00198		\$795,703.00		UNIVERSITY OF TEXAS SYSTEM 166534	110 INNER CAMPUS DR MN 13 AUSTIN	TX 78712-1139	study entitled, "Effect of repeat unit ordering on the properties of meltextruded, poly(lactide-coglycolide)-based, long- acting,implants"
75F40120C00127	Ś	323,132.00	\$ 997 609 00	REGENTS OF THE UNIVERSITY OF MICHIGAN 221536	503 THOMPSON ST ANN ARBOR	MI 48109-1340	study entitled, "Characterization of Exparel®, understanding of critical manufacturing process parameters and characterization of drug release mechanisms in vitro and in vivo."
	·			ST LOUIS COLLEGE OF PHARMACY	4588 PARKVIEW PL		study entitled, "Food and Drug Administration Broad Agency Announcement for the "Robust in vitro/in silico Model to Accelerate Generic Drug Product Development for the Oral Cavity Route of
75F40120C00150 75F40120C00136	\$	1,158,642.00		UNIVERSITY OF CONNECTICUT	438 WHITNEY RD EXTENSION UNIT 1133 STORRS	MO 63110-1088 CT 06269-1133	Administration." study entitled "Assessing Long-Acting Injectable Formulations Using in Vivo Imaging".
75F40120C00172	\$	562,455.00		VIRGINIA COMMONWEALTH UNIVERSITY 164539	912 W FRANKLIN ST RICHMOND	VA 23284-9040	study entitled, "Evaluation of Current Approaches Used to Establish Bioequivalence of Nasal Sprays for Local Action in Children".
75F40120C00125	\$	2,192,399.00		·	RUTGERS, THE STATE UNIVERSITY OF NJ 3 RUTGERS PLZA NEW BRUNSWICK	NJ 08901-8559	study entitled, "Development and Round- Robin Verification of Dynamic RTD Models for the Online Product Quality Analysis".
75F40120C00168	\$	1,256,778.00	\$ 1,256,778.00	RESEARCH CENTER PHARMACEUTICAL ENGINEERING GMBH 1563506	INFFELDGASSE 13 GRAZ	STEIERMARK 8010	study entitled, "Precision modeling tool for evaluating CM Control Approaches: A high-fidelity digital twin for industry and FDA"

			Total Estimated				
Contract Number	Amo	unt Obligated	Contract Value	Awardee Name	Awardee Address	Awardee Zip Code	Description of Requirement
							study entitled, "Immunogenicity Risk of
							Peptide Drug Generics and their Impurities:
					CUBRC, INC.		In
					4455 GENESEE ST STE 106		Silico and In Vitro Assessment and Validation
75F40120C00157	\$	1,160,437.00	\$ 1,160,437.00	CUBRC, INC 405986	BUFFALO	NY 14225-1955	Methods."
							study entitled, "Setting Patient-Centric
					1058 WOLVERINE TOWER - DRDA		Quality Standards (PCQS) for Modified
	١.				3003 S. STATE ST.		Release (MR) Oral Drug Products with
75F40120C00200	\$	2,212,490.00	\$ 2,212,490.00	OF MICHIGAN	ANN ARBOR	MI 48109-1274	Biopredictive in Vitro Dissolution-Models."
							Characterization of Chemical Constituents
				CENTRAL STATE UNIVERSITY	1400 BRUSH ROW RD		from Smokable Hemp Flower and E-
75F40120C00141	\$	1,303,695.00	\$ 1,303,695.00	109828	WILBERFORCE	OH 45384-5800	cigarette.
					00171041 047111007171175 71154		study entitled, "Model-Informed Drug
				CRITICAL RATILINGTITUTE THE	CRITICAL PATH INSTITUTE, THE 1		Development in the Evaluation
75540420600400	_	205 504 00	4 420 040 00	CRITICAL PATH INSTITUTE, THE	1730 E RIVER RD STE 200	47.05740.5000	and Development of Neurological Drug
75F40120C00199	\$	386,681.00	\$ 1,128,848.00	273869	TUCSON	AZ 85718-5893	Products"
							conduct a study entitled, "Innovative
				THE DECENTS OF THE HAILVEDSITY	1050 MOLVEDINE TOWER DRDA		randomized trial design and Bayesian
75540420600405	_ ا	700 670 00	¢ 700 C70 00	THE REGENTS OF THE UNIVERSITY		NAL 40100 1274	analysis for the registration of a drug for rare
75F40120C00195	\$	799,670.00	\$ 799,670.00	OF MICHIGAN	3003 S. STATE ST. ANN ARBOR	MI 48109-1274	disease in small samples"
							study entitled, "Expanding Current and
							Future Susceptibility Testing Criteria with Genotypic Data: Comparative
							Efficacy of Human-Simulated Exposures of
							Ceftazidime/Avibactam,
							Imipenem/Relebactam, and
					HARTFORD HOSPITAL 80 SEYMOUR		Meropenem/Vaborbactam against OXA-48
					c		β-lactamase-producing Enterobacterales in
					80 SEYMOUR ST		the Neutropenic Murine Thigh Infection
75F40120C00152	\$	248,725.00	\$ 248 725 00	HARTFORD HOSPITAL 1364439	HARTFORD	CT 06102-8000	Model".
731 40120000132	+	240,723.00	2-0,723.00	HARTIOND HOSITIAL 1304433	HARTIONS	C1 00102 0000	conduct a study entitled, "Development of
							Modernized Acinetobacter Baumannii
							Susceptibility Guidance for Recommended
				UNIVERSITY OF WISCONSIN			Antimicrobial Agents Using Pharmacometric
75F40120C00111	\$	313,326.00	\$ 313.326.00	SYSTEM 254958	21 N PARK ST STE 6401 MADISON	WI 53715-1218	Approaches."
70. 1022000222	+	0_0,0_0.00	Ψ 010)010:00		HARTFORD HOSPITAL 80 SEYMOUR		study entitled, "Metallo-β-Lactamase
					S		Resistance in Enterobacterales: Is it
					80 SEYMOUR ST		Time to Rethink Our In Vitro Assessment
75F40120C00164	Ś	249,794.00	\$ 249.794.00	HARTFORD HOSPITAL 1364439	HARTFORD	CT 06102-8000	Tools?"
		,					to conduct a study entitled, "Efficacy of
				UNIVERSITY OF PENNYSLVANIA	TRUSTEES OF THE UNIVERSITY OF		Chronic Opioid Pain Treatments: An RCT
75F40120C00175	\$	1,082,140.00	\$ 1,082,140.00		PENNS 3451 WALNUT ST RM 737	PA 19104-6245	Reanalysis"
		· ·	, ,				study entitled "Integrating Clinical trials And
							Real world Endpoints data
				ALLIANCE NCTN FOUNDATION	125 S WACKER DR STE 1600		(ICAREdata) Data Capture and
75F40120C00139	\$	1,502,158.00	\$ 1,502,158.00	1563549	CHICAGO	IL 60606-4404	Standardization Study"

			Total Estimated				
Contract Number	Amo	unt Obligated	Contract Value	Awardee Name	Awardee Address	Awardee Zip Code	Description of Requirement
				WEILL MEDICAL COLLEGE OF	WEILL MEDICAL COLLEGE OF CORNELL UN 407 E 61ST ST RM 106 1ST FL		Development of rabbit animal models of ventilator-associated bacterial pneumonia produced by carbapenem-resistant Pseudomonas
75F40120C00140	\$	994,896.00	\$ 994.896.00	CORNELL UNIVERSITY 141415	NEW YORK	NY 10065-4805	aeruginosa and Acinetobacter baumannii
75F40120C00044	\$	4,419,354.00		BRIGHAM AND WOMENS HOSP	75 FRANCIS ST BOSTON	MA 02115-6110	Study entitled, "Risk Evaluation and Mitigation Strategy (REMS) Programs to Promote Appropriate Medication Use and Knowledge"
75F40120C00156	\$	486,580.00	\$ 486,580.00	ANTICOAGULATION FORUM, INC 1523973	17 LINCOLN STREET NEWTON	MA 02464-1559	Study entitled, "Mentored Implementation and Dissemination of Anticoagulation Stewardship (MIDAS) Program"
75F40120C00126	\$	200,884.00	\$ 435,308.00	CHILDREN'S HOSPITAL, CINCINNATI, OHIO, THE 148252	3333 BURNET AVE CINCINNATI	OH 45229-3026	Study entitled, "Preventable Harm from Pediatric Outpatient Medication Errors: Measure Development"
75F40120C00151	\$	1,152,427.00	\$ 1,152,427.00	DENVER HEALTH AND HOSPITAL AUTHORITY 366859	DENVER HEALTH AND HOSPITALS AUTHORI 777 BANNOCK ST DENVER	CO 80204-4507	Conduct a study entitled, "Evaluation of Stimulant Abuse in the United States: A mosaic epidemiology Study"
75F40120C00033	\$	917,860.88	\$ 3,634,438.08	DELOITTE CONSULTING L.L.P. 116706	1919 N LYNN ST ARLINGTON	VA 22209-1742	Processing and Curation Through the Use of Intelligent Automation and Cloud Enablement."
75F40120C00138	\$	283,619.50	\$ 584,639.00	HUSSON UNIVERSITY 1545484	HUSSON UNIVERSITY 1 COLLEGE CI 1 COLLEGE CIR BANGOR	ME 04401-2929	Study entitled, "Predicting the Transfer of Breast Cancer Resistant Protein (BCRP) Substrates into Human Milk Using In Vitro Extrapolation (IVIVE)"
75F40120C00201	\$	349,364.00	\$ 349,364.00	UNIVERSITY OF CONNECTICUT 297690	438 WHITNEY RD EXTENSION UNIT 1133 STORRS	CT 06269-1133	study entitled, "Continue Processing of Liposomal Nanoparticles as Reference Materials for Dug Product Development".
75F40120C00191	\$	631,011.00	\$ 631,011.00	ALLIANCE NCTN FOUNDATION 1563549	ALLIANCE NCTN FOUNDATION 125 S WACKER DR STE 1600 CHICAGO	IL 60606-4404	Study entitled, "Adverse Event Reporting in the Intergrating Clinical trials And Real world Endpoints data (ICAREdata) Initiative"
75F40120C00122	\$	399,996.00	\$ 399,996.00	NEW YORK UNIVERSITY 178278	NEW YORK UNIVERSITY 550 1ST AVE NEW YORK	NY 10016-6402	Study entitled, "Leveraging the EHR to Promote Pharmacy Adoption of Dosing Best Practices and Reduce Parent Errors in Administering Pediatric Liquid Medications: A Health Literacy-Informed Approach."
75F40120C00123	\$	274,413.00	\$274,413.00	DUKE UNIVERSITY 132317	P O BOX 104004 DURHAM	NC 27708	study entitled, "Using Electronic Health Records to Identify and Assess Adverse Events for Biologic Therapies: Developing and Validating Methodological Approaches."
75F40120C00070	Ś	831,964.00	\$ 831,964.00	RESEARCH CENTER PHARMACEUTICAL ENGINEERING GMBH	RESEARCH CENTER PHARMACEUTICAL ENGI INFFELDGASSE 13 GRAZ	STE 8010	study entitled: "OCT for Real-Time Monitoring of Coating Process Dynamics & Product Quality"

		Total Estimated				
Contract Number	Amount Obligated	Contract Value	Awardee Name	Awardee Address	Awardee Zip Code	Description of Requirement
						study entitled, "A using big data, machine
						learning, and infoveillance approaches to
						detect and characterize adoption and
				S-3 RESEARCH LLC 3636 NOBEL DR		adherence to prep therapy among minority
75F40120C00181	\$ 54,500.00	\$ 54,500.00	S-3 RESEARCH 1564164	STE 170 SAN DIEGO	CA 92122-1042	populations."
						a study entitled, "Pharmacodynamics of
						Minocycline, Levofloxacin, and
						Trimethoprim/sulfamethoxazole against
				HARTFORD HOSPITAL 80 SEYMOUR		Stenotrophomonas maltophilia: Implications
75F40120C00171	\$ 249,991.00	\$ 249,991.00	HARTFORD HOSPITAL 1364439	ST HARTFORD	CT 06102-8000	for Susceptibility Breakpoint Revisions".
			THE RESEARCH FOUNDATION FOR			
			STATE UNIVERSITY OF NEW YORK	FOOLER ENTRANCE STE 244		Conductor of the Conduc
75540420600450	¢ 527.725.00	6 527 725 00	ON BEHALF OF UNIVERSITY OF	520 LEE ENTRANCE, STE 211	NN/44220 2567	Conduct a study entitled, "Evaluating LRT for
75F40120C00159	\$ 527,735.00	\$ 527,735.00	BUFFALO	AMHERST, NY	NY 14228-2567	Post-market surveillance of adverse events."
						Leveraging Community Engagement and
						Electronic Health Record Strategies to
75540120000174	\$ 200,000,00	¢ 1,400,000,00	VALE LINIVEDCITY	10E MALL ST. NEW HAVEN CT	CT 06E11 9017	Promote Diverse Participation in COVID-19
75F40120C00174	\$ 300,000.00	ς 1,439,399.00	YALE UNIVERSITY	105 WALL ST, NEW HAVEN, CT	CT 06511-8917	Clinical Trials
Totals	\$ 55,289,690.12	\$ 71,253,309.81				